Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Developments and Challenges in Liver Transplantation
share announcement

Developments and Challenges in Liver Transplantation

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 506

Special Issue Editor

Dr. Paolo De Simone

E-Mail Website
Guest Editor
Division of Hepatic Surgery and Liver Transplantation, University of Pisa Medical School Hospital, 56126 Pisa, Italy
Interests: liver transplantation; hepatocellular carcinoma; immunosuppression; hepatobiliary surgery; liver diseases; liver cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liver transplantation is one of the main treatments for end-stage liver disease and has made significant progress in recent years. The introduction of new surgical techniques, immunosuppressive drugs, and organ preservation methods has improved the success and survival rates of liver transplantation. However, the problem of donor shortage still exists, and the long-term use of immunosuppressive drugs may lead to side effects and complications. In addition, postoperative care and complication management are critical to patient recovery and survival. This Special Issue will summarize improvements in liver transplantation techniques, donor shortage issues, immunosuppression and rejection, and postoperative care and complication management.

This Special Issue aims to promote scholarly communication and provide valuable information to physicians, researchers, and patients. We invite researchers working in the field of liver transplantation and related areas to submit their findings as original articles or reviews to this Special Issue.

Dr. Paolo De Simone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver transplantation
  • end-stage liver disease
  • organ preservation
  • transplant rejection
  • post-transplantation
  • immunotolerance
  • perioperative care

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

11 pages, 1133 KiB  
Case Report
Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios
by Rita Gaspari, Paola Aceto, Giorgia Spinazzola, Edoardo Piervincenzi, Maurizio Chioffi, Felice Giuliante, Massimo Antonelli and Alfonso Wolfango Avolio
J. Clin. Med. 2024, 13(10), 2853; https://doi.org/10.3390/jcm13102853 - 12 May 2024
Viewed by 234
Abstract
Background: Hepatic dysfunction (HD) after liver transplantation (LT) or extended hepatic resection (EHR) is associated with graft failure and high short-term mortality. We evaluated the safety and depurative efficacy of CytoSorb® in these settings. The primary endpoint was the change in serum [...] Read more.
Background: Hepatic dysfunction (HD) after liver transplantation (LT) or extended hepatic resection (EHR) is associated with graft failure and high short-term mortality. We evaluated the safety and depurative efficacy of CytoSorb® in these settings. The primary endpoint was the change in serum total bilirubin at the end of the treatment compared to the baseline value. The secondary endpoint was to evaluate the trend of serum total bilirubin and coagulation parameters up to 72 h after discontinuation of CytoSorb®. The effects of CytoSorb® therapy on the degree of hepatic encephalopathy (HE), Sequential Organ Failure Assessment (SOFA), and Model for End-Stage Liver Disease (MELD) scores as well as the hemodynamic status compared to baseline were also assessed. Methods: Adult patients with a serum total bilirubin level > 10 mg/dL admitted to the Intensive Care Unit were included. Exclusion criteria were hemodynamic instability, postoperative bleeding and platelet count < 20,000/mm3. Results: Seven patients were treated. Serum total bilirubin was significantly reduced at the end of treatment. However, seventy-two hours after the discontinuation of extracorporeal therapy, bilirubin levels returned to baseline levels in four patients. A decrease in platelet count was found during therapy, and platelet transfusion was required in six cases. A significant increase in D-dimer at the end of treatment was detected. HE degree, SOFA and MELD scores remained stable, while a deterioration in hemodynamic status was observed in two cases. Conclusions: Our preliminary findings did not show the possible benefits of CytoSorb® in rebalancing clinical and laboratory parameters in patients with HD after LT or EHR. Full article
(This article belongs to the Special Issue Developments and Challenges in Liver Transplantation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop